FDA Approved: DYMISTA — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

The FDA approved a supplemental application for DYMISTA, a combination of azelastine hydrochloride and fluticasone propionate, from Viatris Specialty LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• DYMISTA (azelastine hydrochloride and fluticasone propionate)

Snippet

SUPPL AP for DYMISTA (AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE)